Jarl Ulf Jungnelius
Board member
Medical Science
Oncopeptides
Sweden
Biography
Jarl Ulf Jungnelius was appointed to the board of Oncopeptides in April 2011. Ulf is a licensed medical practitioner and a specialist in a number of areas including oncology. He has published a number of scientific articles and has more than 25 years’ experience in leadership positions in both large academic and corporate institutions. He has been instrumental in the development and registration of gemcitabine (Gemzar), premetrexed (Alimta), Sunitinib (Sutent), lenalidomide (Revlimid) and the albumin bound nanoparticle paclitaxel (Abraxane). Born: 1951 Holdings in Oncopeptides: 7,850 shares and 49 Share Options* Other current positions: Director Biovica International AB, Isofol Medical AB, Monocl AB, Noxxon AG and HealthCom GmbH. Independent in relation to the Company, its senior management and major shareholders.
Research Interest
His research interests lie in Healthcare and Medical Sciences. He is the Editor-in-Chief Member of many peer reviewed journals and his area of expertise credits him with many publications in national and international journals. He is committed to highest standards of excellence and it proves through his authorship of many books.
